Skip to search formSkip to main contentSkip to account menu

10,11-methylenedioxycamptothecin

Known as: MDCPT cpd 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Camptothecin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Hydrophilic Camptothecin Analogs That Form Extremely Stable Cleavable Complexes with DNA and Topoisomerase I
Camptothecin (CPT) analogs that form more stable ternary complexes with DNA and topoisomerase I (termed cleavable complexes) show… 
2001
2001
UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice.
UCN-01 is a hydroxylated derivative of staurosporine and a potent protein kinase C (PKC) inhibitor. Interest in the potential… 
1996
1996
Camptothecin post‐treatments inhibit the biochemical events linked to the tumor‐promoting component of carcinogenesis in mouse epidermis in vivo
20(S)‐Camptothecin (CPT), a topoisomerase I inhibitor specifically toxic toward S‐phase cells, was tested topically for its… 
1991
1991
S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells.
Previous studies in rapidly proliferating rodent cells have suggested that the lethal effect of the DNA topoisomerase I inhibitor… 
1990
1990
10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells.
We had previously shown that 10,11-methylenedioxy-20-(RS)-camptothecin (MDO-CPT) is a more potent inhibitor of purified DNA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)